Hypnite (Eszopiclone) 1 mg
โฑ Shown in your currency
๐ Hypnite 1 mg (Eszopiclone) โ Gentle & Effective Sleep Aid
๐ Product Details
-
Active Ingredient (Generic Name): Eszopiclone
-
Manufacturer: Consern Pharma Pvt. Ltd.
-
Packaging: 10 tablets in 1 strip
-
Strength: 1 mg
-
Delivery Time: 6 to 15 days
-
SKU: Hypnite 1 MG
โจ Product Overview
Hypnite 1 mg contains Eszopiclone, a modern sleep-inducing medication that helps treat insomnia and difficulty falling or staying asleep.
Manufactured by Consern Pharma, it works by calming brain activity and promoting natural, restorative sleep.
This 1 mg strength is ideal for individuals who need mild support for sleep onset without excessive sedation or next-day grogginess.
๐ Key Benefits
-
๐ Helps You Fall Asleep Faster: Reduces time to sleep onset
-
๐ด Improves Sleep Quality: Encourages deep, refreshing sleep
-
๐ง Eases Anxiety & Nighttime Restlessness
-
๐ผ Minimizes Next-Day Drowsiness: Wake up clear-headed and alert
-
๐ Trusted Sleep Solution โ Consern Pharma
๐ก Usage Instructions
-
Take 1 tablet (1 mg) orally with water just before bedtime.
-
Only take when you can get 7โ8 hours of sleep.
-
Swallow the tablet whole; do not chew or crush.
-
Avoid alcohol and other sedatives while taking Hypnite.
-
Use for short-term treatment (2โ4 weeks) unless prescribed otherwise by your doctor.
โ ๏ธ Important Information
-
Not suitable for individuals with severe liver impairment, sleep apnea, or a history of substance dependence.
-
Common mild side effects: metallic taste, dry mouth, dizziness, or mild headache.
-
Avoid driving or operating machinery after taking the dose.
-
Not advised during pregnancy or breastfeeding without medical guidance.
-
Use strictly under doctorโs supervision for safe and effective results.
๐ Hypnite 1 mg (Eszopiclone) provides gentle, natural sleep support โ helping you fall asleep easily, stay asleep longer, and wake up feeling refreshed and renewed. ๐๐คโจ
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.